Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

Trial Profile

Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 24 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 29 Sep 2016 New source identified and integrated (European Clinical Trials Database; EudraCT2016-000613-79)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top